Figure 1.
Anlotinib inhibits proliferation of KRAS mutant lung cancer cells. (A and B) KRAS mutation sites of A549 and NCI-H460 cells (G12S and Q61H, respectively). (C) Cell inhibition rate with Anlotinib treatment. (D) Phase contrast microphotograph images of lung cancer cells with or without Anlotinib for 48h. (E) Colony formation after Anlotinib treatment. *P<0.05, **P<0.01
